Orphan Receptor Drug Discovery

In a climate favoring defined clinical product opportunities, venture capitalists have had a hard time seeing the value proposition in investing in orphan nuclear receptor drug discovery. These targets likely modulate a range of diseases, but the disease associations are undetermined. Orphan receptors are also difficult targets for drug screening. Nonetheless, a handful of start-ups are taking up the drug discovery challenge.

In a climate favoring defined clinical product opportunities, it's no wonder venture capitalists have a hard time seeing the value proposition in investing in orphan nuclear receptor drug discovery. Orphans raise red flags because the correlation between activation of orphan receptors and the corresponding role in the development, initiation, or progression of specific diseases is not known. Plus, companies have not yet shown that they can leverage a discovery technology platform across several orphan receptor targets.

Nuclear receptors are a set of hormone-dependent and hormone-independent transcription factors that are responsible for reproduction, growth, differentiation, and homeostasis. They are part of a large superfamily consisting of receptors...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Business

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.